Last reviewed · How we verify
Pirfenidone Capsules (400 mg) — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Pirfenidone Capsules (400 mg) (Pirfenidone Capsules (400 mg)) — Beijing Continent Pharmaceutical Co, Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pirfenidone Capsules (400 mg) TARGET | Pirfenidone Capsules (400 mg) | Beijing Continent Pharmaceutical Co, Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pirfenidone Capsules (400 mg) CI watch — RSS
- Pirfenidone Capsules (400 mg) CI watch — Atom
- Pirfenidone Capsules (400 mg) CI watch — JSON
- Pirfenidone Capsules (400 mg) alone — RSS
Cite this brief
Drug Landscape (2026). Pirfenidone Capsules (400 mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/pirfenidone-capsules-400-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab